Orthocell (ASX:OCC) has confirmed it’s sold its first units of collagen-based bone repair product Striate+ in Canada through distro partner BioHorizons.
The move effectively represents a further expansion for the company into another western market after reported success in Australia, the US, EU, and Uk. In July, the company noted it had clocked record revenue.
As in other markets, Orthocell’s sales strategy in Canada is targeting the dental market where Striate+ has been shown to receive the most enthusiasm. Health Canada greenlit sales back in July.
Orthocell on Friday pointed to a recent post-market clinical study that clocked a success rate over 98% with regards to ‘fixing’ teeth using the company’s collagen-based product.
“Commencement of sales in Canada is further validation of Orthocell’s expanding global footprint. Our valued partner BioHorizons has executed a rapid transition from approval to first sales,” Orthocell MD Paul Anderson said.
“This reaffirms the high-quality nature of our product and partnership. Once Singapore and Brazil applications are approved, Striate+ will be available for use in guided bone and tissue repair in seven large and attractive markets.”
OCC last traded at 39cps.